

# Psoriasis Case Consult 2

## A Case of Psoriasis in a Patient With Depression and History of Malignancy

### References

- Armstrong AW, Papp KA, Zhuo J, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2. *SKIN J Cutan Med.* 2022;6(6): s63.
- aArmstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials. *SKIN J Cutan Med.* 2023;7(6):s240.
- bArmstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: A network meta-analysis. *Dermatol Ther (Heidelb).* 2023;13(11):2839-2857.
- Armstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: 4-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at: European Academy of Dermatology & Venereology Symposium; May 16-18, 2024; St Julians, Malta.
- da Silva N, Augustin M, Hilbring C, Braren-von Stülpnagel CC, Sommer R. Psychological (co)morbidity in patients with psoriasis: the impact of pruritus and anogenital involvement on symptoms of depression and anxiety and on body dysmorphic concerns—a cross-sectional study. *BMJ Open.* 2022;12(9):e055477.
- Furtunescu AR, Georgescu SR, Tampa M, Matei C. Inhibition of the JAK-STAT pathway in the treatment of psoriasis: A review of the literature. *Int J Mol Sci.* 2024;25(9):4681.
- Guo M, Su J, Zheng S, Chen B. Sleep in psoriasis: A meta-analysis. *J Psychosom Res.* 2024;176:111543.
- Hölsken S, Krefting F, Schedlowski M, Sondermann W. Common fundamentals of psoriasis and depression. *Acta Derm Venereol.* 2021;101(11):adv00609.
- Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: Focus on psoriasis comorbidities. *BioDrugs.* 2023;37(1):35-55.
- Jung JM, Kim YJ, Chang SE, Lee MW, Won CH, Lee WJ. Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study. *J Cancer Res Clin Oncol.* 2023;149(19):17093-17102.
- Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. *Br J Dermatol.* 2024;190(5):668-679.
- Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. *J Eur Acad Dermatol Venereol.* 2017;31(12):1999-2009.
- Martins AM, Ascenso A, Ribeiro HM, Marto J. The Brain-skin connection and the pathogenesis of psoriasis: A review with a focus on the serotonergic system. *Cells.* 2020;9(4):796.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019;80(4):1029-1072.
- Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. TYK2: an emerging therapeutic target in rheumatic disease. *Nat Rev Rheumatol.* 2024;20(4):232-240.

- Mrowietz U, Sümbül M, Gerdes S. Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation. *J Eur Acad Dermatol Venereol*. 2023;37(9):1731-1738.
  - Sahin E, Hawro M, Weller K, et al. Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. *J Eur Acad Dermatol Venereol*. 2022;36(5):688-697.
  - Strand V, Gossec L, Coates LC, et al. Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized phase 2 trial. *Arthritis Care Res (Hoboken)*. 2024 Mar 26. [Online ahead of print] doi:10.1002/acr.25333
  - Strober B, Soliman AM, Truong B, Patel MB, Barqawi YK, Gisondi P. Association between biologic exposure and the risk of depression in patients with psoriasis: A retrospective analysis of large US administrative claims data. *Am J Clin Dermatol*. 2024 Jun 27. [Online ahead of print] doi: 10.1007/s40257-024-00877-w
  - Svedbom A, Ståhle M. Interleukin-17 and -23 inhibitors associated with direct effects on depressive symptoms in psoriasis: results from a register study. *Acta Derm Venereol*. 2023;103:adv7138.
  - Tabra SA, Abd Elghany SE, Amer RA, Fouda MH, Abu-Zaid MH. Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients. *Clin Rheumatol*. 2022;41(11):3391-3399.
  - Timis TL, Beni L, Mocan T, Florian IA, Orasan RI. Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients. *Life (Basel)*. 2023;13(5):1219.
  - Tong N, Zhang Y, Yang A, Dai X, Hao S. The potency of common proinflammatory cytokines measurement for revealing the risk and severity of anxiety and depression in psoriasis patients. *J Clin Lab Anal*. 2022;36(9):e24643.
  - Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis. *JAMA Dermatol*. 2020;156(4):421-429.
  - Wannarit K, Wongpraparut C, Chularojanamontri L, et al. Prevalence of depressive symptoms and their impact on perceived stress and quality of life among patients with psoriasis. *Alpha Psychiatry*. 2023;24(6):239-243.
  - Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N Engl J Med*. 2022;386(4):316-326.
-